Association of unplanned hospitalizations after chemotherapy with disease specific survival in a racially ethnically diverse population of women with epithelial ovarian cancer.

ObjectiveBoth pre-treatment prognostic nutritional index and platelet count were reported to be independent prognostic factors in epithelial ovarian cancer patients. However, their relationship has not been investigated. The aim of this study was to investigate the association between the pre-treatment prognostic nutritional index and platelet count, and to compare their utility as prognostic indicators for patients with epithelial ovarian cancer.MethodsClinical data from epithelial ovarian cancer patients treated between April 2007 and March 2016 were collected and retrospectively reviewed. The association between the pre-treatment prognostic nutritional index and platelet count was evaluated using Spearman’s rank correlation coefficient. After determining the cut-off values for the pre-treatment platelet count and prognostic nutritional index for predicting disease-specific survival by time-dependent receiver operating characteristic (ROC) curve analysis, we compared the clinical utility of platelet counts and the prognostic nutritional index.ResultsA total of 308 patients were included in the analysis. Median age was 57 (range 16–81) years. The International Federation of Gynecology and Obstetrics (FIGO) clinical stage at initial diagnosis was stage I in 137 patients (44.5%), stage II in 27 patients (8.8%), stage III in 96 patients (31.2%), and stage IV in 48 patients (15.6%). Most patients (37.7%) had serous adenocarcinoma. Of the 295 patients who underwent primary or interval debulking surgery, optimal debulking was performed in 240 patients (77.9%). Decresed pre-treatment prognostic nutritional index was correlated with increased pre-treatment platelet count (p<0.0001), and when compared, the prognostic nutritional index had a significantly greater area under the ROC curve value than the platelet count for predicting disease-specific survival (0.8348 vs 0.6413, p=0.0007). An elevated platelet count was significantly associated with a shorter disease-specific survival in epithelial ovarian cancer patients (p<0.0001). However, when the prognostic nutritional index was adjusted, an elevated platelet count did not provide any prognostic information (lower prognostic nutritional index, p=0.45; higher prognostic nutritional index, p=0.77).ConclusionsThe pre-treatment prognostic nutritional index was superior to the platelet count for predicting disease-specific survival for epithelial ovarian cancer patients. Although pre-treatment thrombocytosis was reported to be an independent poor prognostic factor in epithelial ovarian cancer patients, it generally reflects a lower prognostic nutritional index, and did not provide any prognostic information when the prognostic nutritional index was adjusted.

Download Full-text

Prevalence and opinions regarding BRCA genetic testing and counseling in a racially and ethnically diverse population of women with epithelial ovarian cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.05.454 ◽

2020 ◽

Vol 159 ◽

pp. 262-263

Author(s):

R. Borczuk ◽

M.A. Gardin ◽

O.R. Khouri ◽

S.M. Dolan ◽

S.K. Gorobetz ◽

...

Keyword(s):

Ovarian Cancer ◽

Genetic Testing ◽

Epithelial Ovarian Cancer ◽

Ethnically Diverse ◽

Diverse Population ◽

Brca Genetic Testing ◽

Testing And Counseling

Download Full-text

Abstract P1-10-05: Analysis of genetic mutation in ethnically diverse population with Breast and ovarian cancer: Single institution experience

10.1158/1538-7445.sabcs18-p1-10-05 ◽

2019 ◽

Author(s):

S Aggarwal ◽

C Chu ◽

M Ngumi

Keyword(s):

Ovarian Cancer ◽

Ethnically Diverse ◽

Genetic Mutation ◽

Diverse Population ◽

Single Institution ◽

Breast And Ovarian Cancer

Download Full-text

Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer

Journal of Gynecologic Oncology ◽

10.3802/jgo.2017.28.e7 ◽

2017 ◽

Vol 28 (1) ◽

Cited By ~ 13

Author(s):

Nienke Zwakman ◽

Rafli van de Laar ◽

Toon Van Gorp ◽

Petra LM Zusterzeel ◽

Marc PML Snijders ◽

...

Keyword(s):

Ovarian Cancer ◽

Prognostic Factor ◽

Disease Specific Survival ◽

Serum Ca125 ◽

Disease Specific

Download Full-text

Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.5058 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 5058-5058

Author(s):

D. S. Chi ◽

Y. Sonoda ◽

N. R. Abu-Rustum ◽

C. S. Awtrey ◽

J. Huh ◽

...

Keyword(s):

Ovarian Cancer ◽

Ovarian Carcinoma ◽

Cytoreductive Surgery ◽

Predictor Variables ◽

Concordance Index ◽

Disease Specific Survival ◽

Stage Iiic ◽

Term Survival ◽

Accuracy Measure ◽

Disease Specific

5058 Background: Nomograms have been developed for numerous malignancies to predict a specific individual’s probability of long-term survival based on known prognostic factors. To date, no prediction model has been developed for patients with ovarian cancer. The objective of this study was to develop a nomogram to predict the probability of 4-year survival after primary cytoreductive surgery for bulky stage IIIC ovarian carcinoma. Methods: Nomogram predictor variables included age, tumor grade, histologic type, preoperative platelet count, the presence or absence of ascites, and residual disease status after primary cytoreduction. Disease-specific survival was estimated using the Kaplan-Meier method. Cox proportional hazards regression was used for multivariable analysis. The Cox model was the basis for the nomogram. The concordance index was used as an accuracy measure, with bootstrapping to correct for optimistic bias. Calibration plots were constructed. Results: A total of 462patients with bulky stage IIIC ovarian carcinoma underwent primary cytoreductive surgery at our institution during the study period of 1/89 to 12/03, of whom 397 were evaluable for inclusion in the study. The median age of the study population was 60 years (range 22–87). The primary surgeon in all cases was an attending gynecologic oncologist. Postoperatively, all patients received platinum-based systemic chemotherapy. Ovarian cancer-specific survival at 4 years was 51%. A nomogram was constructed on the basis of a Cox regression model and the 6 predictor variables. This nomogram was internally validated using bootstrapping and shown to have excellent calibration with a bootstrap-corrected concordance index of 0.67. Conclusions: A nomogram was developed to predict 4-year disease-specific survival after primary cytoreductive surgery for bulky stage IIIC ovarian carcinoma. The nomogram utilizes 6 predictor variables that are readily accessible, assigns a point value to each variable, and then predicts the probability of 4-year survival based on the total point value for an individual patient. This tool should be useful for patient counseling, clinical trial eligibility determination, postoperative management, and follow-up. No significant financial relationships to disclose.

Download Full-text

BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups

10.26226/morressier.5770e29bd462b80290b4bb80 ◽

2016 ◽

Author(s):

Tamar Safra

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Ethnically Diverse ◽

Brca Mutations ◽

Diverse Groups

Download Full-text

The therapeutic benefit of extensive lymphadenectomy in advanced stage ovarian cancer

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.15010 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 15010-15010

Author(s):

J. S. Berek ◽

N. Karnik Lee ◽

M. K. Cheung ◽

K. Osann ◽

A. Husain ◽

...

Keyword(s):

Ovarian Cancer ◽

Germ Cell ◽

Clear Cell ◽

Cox Proportional Hazards ◽

Stage Iiib ◽

Study Group ◽

Advanced Stage ◽

Disease Specific Survival ◽

Extensive Lymphadenectomy ◽

Disease Specific

15010 Background: To determine if extent of lymphadenectomy affects the disease-specific survival of women with advanced-stage ovarian cancer. Methods: Demographic and clinico-pathologic information were obtained from the Surveillance, Epidemiology and End Results Program from 1988–2001 and analyzed using Kaplan-Meier methods and Cox proportional hazards regression. Results: Of the 15,320 women with stage IIIB-IV disease, 763 (5.0%) had stage IIIB, 5,266 (34.4%) stage IIIC, and 9,291 (60.7%) had stage IV disease. The median age was 66 (range: 1–101). 13,251 (86.5%) were White, 1,049 (6.9%) Black, 716 (4.7%) Asian, and 304 (1.9%) were Other. Of the patients who underwent a lymphadenectomy, the median number of nodes resected was 6 (range: 1–90). We divided our study group 3 groups based on the extent of lymphadenectomy (0, <10, 10–20, and >20). In the overall study group, the extent of lymphadenectomy improved the survival from 21.1%, 40.5%, 45.1% to 46.0%, respectively (p < 0.001). Patients with stage IIIB, IIIC, and IV disease had an improvement in survival associated with lymphadenectomy (see table ). In patients with non-clear cell epithelial carcinoma, the extent of lymphadenectomy was associated with improved survivals 20.9%, 39.8%, 45.4%, and 45.9%, respectively (p < 0.0001). Moreover, those with clear cell cancers (p = 0.0001), germ cell (p = 0.001) and sarcomas of the ovary (p = 0.02) also had a survival benefit; however no benefit was demonstrated in sex cord stromal tumors (p = 0.99). In multivariate analysis, a more extensive lymphadenectomy remained significant as an independent prognostic factor for improved survival after adjusting for all other independent prognostic factors including age, year of diagnosis, surgery, histology, stage, and grade. Conclusions: Our findings suggest that the extent of lymphadenectomy improves the disease-specific survival of women with stage IIIB-IV ovarian cancer. This benefit was demonstrated in epithelial, germ cell, and sarcomas of the ovary. [Table: see text] No significant financial relationships to disclose.

Download Full-text